Precision-Panc Master Protocol: Personalising Treatment for Pancreatic Cancer

Launched by JUDITH DIXON-HUGHES · Nov 11, 2019

Keywords

ClinConnect Summary

The Precision-Panc Master Protocol is a clinical trial designed to help personalize treatment for patients with pancreatic cancer. It serves as a way for patients who have either a suspected or confirmed diagnosis of pancreatic cancer to explore different treatment options through various research studies. Patients will undergo a procedure to collect a small sample of their tumor and some blood, which will be sent to a central lab for detailed analysis. The information from these tests will help doctors understand the best treatment options for each individual and may allow patients to join other studies that are testing new therapies.

To be eligible for this trial, participants must be adults over the age of 16 and have either a suspicious pancreatic mass or a confirmed diagnosis of pancreatic ductal adenocarcinoma. They should be willing to undergo an additional biopsy if needed and be considered suitable for treatments like chemotherapy, radiotherapy, or surgery. Participants will need to sign consent forms to take part in the trial and allow their tumor tissue to be used for testing. This trial is currently recruiting patients, and it provides a valuable opportunity for individuals to contribute to research that may lead to better, more personalized treatments for pancreatic cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients (age \>16 years).
• * Either:
• • Presence of a hypodense pancreatic mass highly suspicious of primary pancreatic cancer with or without distant metastasis as assessed by a Pancreatic Multi-Disciplinary Team (MDT).
• • Or
• • o Histologically or cytologically confirmed pancreatic ductal adenocarcinoma and its variants.
• • Patient is willing and able to undergo additional tumour biopsy (from the primary or a metastatic site) aimed at obtaining sufficient tissue for molecular profiling if this is required.
• • Patient is deemed suitable to receive chemotherapy and/or radiotherapy, and/or surgery pending stage of disease at presentation.
• • Patient is deemed potentially eligible for a currently open PRIMUS study
• • Patient has signed informed consent for screening research tumour biopsy (Consent 1).
• • Patient has signed informed consent for Precision-Panc Master Protocol molecular profiling (Consent 2).